May 30 (Reuters) - The U.S. Food and Drug Administration has allowed expanded use of Bristol Myers Squibb's cell therapy, Breyanzi, for an aggressive and rare type of blood cancer that affects the body's disease fighting cells, the company said on Thursday. (Reporting by Bhanvi Satija and Sneha S K in Bengaluru; Editing by Krishna Chandra Eluri)